|
Gene: ZNF527 |
Gene summary for ZNF527 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF527 | Gene ID | 84503 |
Gene name | zinc finger protein 527 | |
Gene Alias | ZNF527 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8NB42 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84503 | ZNF527 | HCC1 | Human | Liver | HCC | 5.56e-11 | 1.24e+00 | 0.5336 |
84503 | ZNF527 | HCC2 | Human | Liver | HCC | 2.41e-23 | 2.42e+00 | 0.5341 |
84503 | ZNF527 | HCC5 | Human | Liver | HCC | 5.98e-16 | 1.38e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF527 | SNV | Missense_Mutation | c.261N>T | p.Trp87Cys | p.W87C | Q8NB42 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-EP-A12J-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF527 | SNV | Missense_Mutation | rs746246081 | c.472A>G | p.Thr158Ala | p.T158A | Q8NB42 | protein_coding | tolerated(0.36) | benign(0) | TCGA-05-4249-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF527 | SNV | Missense_Mutation | novel | c.1277N>C | p.Arg426Pro | p.R426P | Q8NB42 | protein_coding | tolerated(0.19) | benign(0.275) | TCGA-38-7271-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ZNF527 | SNV | Missense_Mutation | c.1469N>C | p.Arg490Thr | p.R490T | Q8NB42 | protein_coding | deleterious(0) | benign(0.402) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF527 | SNV | Missense_Mutation | c.1733N>C | p.Gly578Ala | p.G578A | Q8NB42 | protein_coding | deleterious(0.03) | possibly_damaging(0.56) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ZNF527 | SNV | Missense_Mutation | c.84N>T | p.Trp28Cys | p.W28C | Q8NB42 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-62-A46O-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZNF527 | SNV | Missense_Mutation | c.841N>A | p.Asp281Asn | p.D281N | Q8NB42 | protein_coding | deleterious(0.04) | benign(0) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF527 | SNV | Missense_Mutation | novel | c.836N>A | p.Cys279Tyr | p.C279Y | Q8NB42 | protein_coding | deleterious(0.03) | benign(0.005) | TCGA-MP-A4T4-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF527 | SNV | Missense_Mutation | rs759632113 | c.1361G>T | p.Arg454Leu | p.R454L | Q8NB42 | protein_coding | tolerated(0.33) | benign(0.03) | TCGA-18-4083-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
ZNF527 | SNV | Missense_Mutation | c.50N>T | p.Arg17Ile | p.R17I | Q8NB42 | protein_coding | deleterious(0.01) | benign(0.31) | TCGA-22-1012-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |